8 years ago

Zilico Raises $19M to Expand Cervical Cancer Diagnostic System Globally

  • Zilico, a UK-based developer of a cervical cancer diagnostic system, has raised a total of $19 million in funding

  • The funding includes a $12 million minimum royalty payment and $7 million in investments from MaxHealth Medicine Group and Deepbridge Capital

  • Zilico will use the funds to continue its global expansion plans for ZedScan™ across the UK, Europe, and China, and to take the product through its regulatory trials in the US.

      • ProblemHealthcare

      "Cervical cancer is a major global health concern, with millions of women at risk. Current screening methods, such as Pap smears, are often unreliable and inconvenient."

      Solution

      "Zilico has developed ZedScan™, a non-invasive, painless device that uses electrical impedance spectroscopy (EIS) technology to detect precancerous lesions in the cervix. The device provides real-time results, reducing the need for multiple biopsies and allowing for early intervention and treatment."

      Covered on